<a target=_blank class=ftalternatingbarlinklarge href="http://www.schaeffersresearch.com/plus/archive_commentary.aspx?ID=18630
">http://www.schaeffersresearch....mentary.aspx?ID=18630
</a>
Finally, Gilead Sciences (GILD: sentiment, chart, options) enjoyed an upgrade from "neutral" to "buy" at Merrill Lynch. The brokerage firm listed improved prospects for long-term growth from the company's HIV franchise for the ratings boost. In addition, the firm stated that it believes the 2007 and 2008 launches of its cystic fibrosis and pulmonary arterial hypertension drugs could surprise to the upside. Merrill expects the approval of Ambrisentan for pulmonary arterial hypertension by<b> mid-2007 and the launch of Aztreonam for cystic fibrosis in mid-2008.</b>
Darn. I was hoping it would be this year.
">http://www.schaeffersresearch....mentary.aspx?ID=18630
</a>
Finally, Gilead Sciences (GILD: sentiment, chart, options) enjoyed an upgrade from "neutral" to "buy" at Merrill Lynch. The brokerage firm listed improved prospects for long-term growth from the company's HIV franchise for the ratings boost. In addition, the firm stated that it believes the 2007 and 2008 launches of its cystic fibrosis and pulmonary arterial hypertension drugs could surprise to the upside. Merrill expects the approval of Ambrisentan for pulmonary arterial hypertension by<b> mid-2007 and the launch of Aztreonam for cystic fibrosis in mid-2008.</b>
Darn. I was hoping it would be this year.